Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

Phase 4

Completed

Conditions: Heart Transplantation

Interventions: Drug: Daclizumab
Drug: Methylprednisolone
Drug: Placebo
Drug: Mycophenolate mofetil
Drug: cyclosporine

First Posted Date: 2002-10-25

Last Posted Date: 2016-06-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 434

Registration Number: NCT00048165

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: F-18 Fluorodeoxyglucose
Biological: therapeutic allogeneic lymphocytes
Procedure: Peripheral Blood Stem Cell donation
Drug: cyclophosphamide
Drug: cyclosporine
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: fludarabine phosphate
Drug: melphalan
Drug: prednisone
Drug: sirolimus
Drug: tacrolimus
Drug: vincristine sulfate
Procedure: peripheral blood stem cell transplantation
Drug: Filgrastim

First Posted Date: 2002-08-16

Last Posted Date: 2017-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00043979

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Phase 2

Completed

Conditions: Graft Rejection
Kidney Transplantation
Renal Transplantation

Interventions: Drug: Cyclosporine
Drug: Belatacept
Drug: Mycophenolate mofetil (MMF)
Drug: Corticosteroids

First Posted Date: 2002-05-06

Last Posted Date: 2014-01-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 230

Registration Number: NCT00035555

Locations: 🇺🇸
Medical Univ. of South Carolina, Charleston, South Carolina, United States
🇺🇸
Univ. of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 9 locations

Increasing HAART-Induced Immune Restoration With Cyclosporine

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2002-02-22

Last Posted Date: 2015-03-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00031070

Locations: 🇺🇸
Univ of Texas, Southwestern Med Ctr of Dallas, Dallas, Texas, United States
🇺🇸
Washington Univ (St. Louis), St. Louis, Missouri, United States
🇺🇸
University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States

and more 12 locations

Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia

Phase 2

Completed

Conditions: Hematologic Diseases
Beta-Thalassemia
Hematopoietic Stem Cell Transplantation
Anemia, Sickle Cell

First Posted Date: 2002-01-11

Last Posted Date: 2016-07-29

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 30

Registration Number: NCT00029380

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸
Children's Hospital, Oakland, Oakland, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 12 locations

Study of Muromonab-CD3 and Cyclosporine in Patients With Giant Cell Myocarditis

Not Applicable

Completed

Conditions: Myocarditis

First Posted Date: 2001-12-07

Last Posted Date: 2015-03-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 40

Registration Number: NCT00027443

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Steroid Withdrawal in Pediatric Kidney Transplant Recipients

Phase 2

Terminated

Conditions: End-Stage Renal Disease

Interventions: Drug: Basiliximab
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Sirolimus
Drug: Methylprednisolone
Drug: Prednisone
Drug: Bactrim

First Posted Date: 2001-08-31

Last Posted Date: 2016-10-21

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 274

Registration Number: NCT00023244

Locations: 🇺🇸
University of Florida Health Science Center, Jacksonville, Florida, United States
🇺🇸
The Children's Hospital of Buffalo, Buffalo, New York, United States
🇺🇸
Westchester Medical Center, Valhalla, New York, United States

and more 16 locations

A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Phase 3

Terminated

Conditions: End-Stage Renal Disease
Kidney Transplantation

Interventions: Drug: Cyclosporine
Drug: Sirolimus
Drug: Tacrolimus

First Posted Date: 2001-08-31

Last Posted Date: 2012-03-13

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 102

Registration Number: NCT00005113

Locations: 🇺🇸
Children's Hospital Boston, Boston, Massachusetts, United States

A Study to Test the Effect of Cyclosporine on the Immune System of Patients With Early HIV Disease

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2021-10-28

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 30

Registration Number: NCT00000880

Locations: 🇺🇸
Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
🇺🇸
Beth Israel Med Ctr, New York, New York, United States
🇺🇸
Univ of North Carolina, Chapel Hill, North Carolina, United States

and more 9 locations

Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia

Not Applicable

Conditions: Graft Versus Host Disease
Aplastic Anemia

First Posted Date: 2001-06-06

Last Posted Date: 2005-06-24

Lead Sponsor: Northwestern Memorial Hospital

Target Recruit Count: 3

Registration Number: NCT00017654

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy